Search results
‘I can’t explain why’: Does this dog dewormer cure cancer? These Facebook groups say yes
The Daily Dot· 6 days agoThree months later, the cancer had grown. From a cattle farm in Louisiana where she’s helping a...
Coeur d'Alene couple: 'We just keep fighting'
Coeur d'Alene Press· 1 day agoCOEUR d’ALENE — Steve Prosch has been battling cancer for nearly a decade. On a recent doctor visit, the Coeur d’Alene man was told he had months to...
A human-performance scientist shares the 9 supplements he takes daily for gut, brain, and muscle...
INSIDER via Yahoo News· 1 day agoProfessor Andy Galpin, whose clients include the LA Clippers and Travis Barker, adjusts his daily...
Lack of Insurance Keeps Many Americans From Best Cancer Meds
US News & World Report· 2 days agoA cutting-edge class of drugs is saving and extending the lives of cancer patients. New policies are needed "to improve health insurance coverage options and to make new treatments ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 6 days agoPhase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment for uHCCFinal analysis reported the longest median overall survival for
Breast Cancer Treatment Doesn't Bar Motherhood for Most Women
WebMD· 6 days agoMaggie Louks was diagnosed with breast cancer 12 years ago at the age of 28. Louks’s doctors wanted to treat her cancer aggressively, given the fact she ...
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in...
Benzinga· 4 days agoSUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for < ...
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With...
Benzinga· 3 days agoData show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; "ITT") who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line
A human-performance scientist shares the 9 supplements he takes daily for gut, brain, and muscle...
Business Insider· 1 day agoThis story is available exclusively to Business Insider subscribers. Become an Insider and start...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 days agoInnovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer ...